Home › Myelofibrosis › New Jersey
Myelofibrosis clinical trials in New Jersey
6 studies for Myelofibrosis are looking for participants at sites in New Jersey.
Cities in New Jersey
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
- John Theurer Cancer Center at Hackensack University Medical Center, Hackensack
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT04176198A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
- Summit Medical Group Oncology, Berkeley Heights
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07357727Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
- START New Jersey, East Brunswick
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT05320198A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 28, 2026 · NCT06773195SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, New Brunswick
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
- Hackensack University Medical Center, Hackensack
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2025 · NCT06479135From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.